Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...
The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...
Panelists discuss how dermatologic toxicities from EGFR-targeted therapies can be effectively managed through a comprehensive approach combining prophylactic measures, early interventions with oral ...
Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs ...
"When most people hear the words palliative care, they immediately think about hospice or end-of-life care. This includes ...
Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to ...
Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...
Lenvatinib showed a median PFS of 5.4 months in advanced HCC patients following treatment with atezolizumab/bevacizumab, meeting the primary endpoint. Second-line ...
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback